Back to News
Market Impact: 0.2
Wall Street Analysts Predict a 73.95% Upside in Immunome (IMNM): Here's What You Should Know
Source: zacks.com
Analyst EstimatesAnalyst InsightsHealthcare & Biotech
Consensus price targets imply 74% upside potential for Immunome (IMNM), but the article cautions that this metric has limited empirical effectiveness. Upward earnings-estimate revisions may support near-term gains; no specific target price or revision magnitude is provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
IMNM0.20
More News
- Up 37% since March - this AI-picked IT services stock keeps climbing
- We're cutting our Qnity price target but still loved the beat-and-raise quarter
- How Abdul El-Sayed would build Medicare for All, from a wealth tax to a Fed-style governing board
- BillionToOne SVP John ten Bosch sells $320,723 in stock
- Defense stocks slide on fear Democrats will curb spending. One analyst say it's a buying opportunity
- CVS Plans to Break Up $117 Billion Healthcare Conglomerate